The USPTO has granted Galectin Therapeutics a notice of issuance for a patent covering methods of derivation and use for carbohydrate-based galectin inhibitor compound for use in patients with chronic liver disease associated with the development of fibrosis, established liver fibrosis or end-stage scarring, or cirrhosis.
The major claim is for a method of obtaining the galectin inhibitor compound, obtaining a composition for parenteral administration in an acceptable pharmaceutical carrier and administering to a subject having either chronic liver disease associated with the development of fibrosis, established liver fibrosis or cirrhosis.
Galectin president, CEO and CMO Peter Traber said, "The issuance of this patent asserts Galectin Therapeutics as the leader in developing galectin inhibitors for the treatment of liver fibrosis, and its broad coverage allows us protection as we explore the range of liver fibrosis for which our compounds could be efficacious."
The use covers inhibiting or slowing the progression of fibrosis or the reversal of fibrosis, according to the company.
GR-MD-02, the lead compound in development for NASH with fibrosis, is covered by the patent and provides opportunities for development of additional compounds in the class.
